Redhill Biopharma Ltd. (RDHL) SEC Filing 6-K Foreign Issuer Report for the period ending Tuesday, March 15, 2022

Redhill Biopharma Ltd.

CIK: 1553846 Ticker: RDHL

Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of March 2022
Commission File No.:001-35773
(Translation of registrant’s name into English)
21 Ha'arba'a Street, Tel Aviv, 6473921, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  

Form 20-F  Form 40-F
Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ 
Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Attached hereto as Exhibit 99.1 and incorporated by reference herein is a press release issued by the Registrant on March 15, 2022, entitled: “RedHill and Kukbo Enter Oral Opaganib License for COVID-19 in South Korea”.
This Report on Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776) on March 25, 2021 (File No. 333-254692) and on May 3, 2021 (File No. 333-255710), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 24, 2019 (File No. 333-232777), on March 30, 2021 (File No. 333-254848) and on July 29, 2021 (File No. 333-258259).

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

(the "Registrant")
Date: March 15, 2022
 /s/ Dror Ben-Asher 
Dror Ben-Asher 
Chief Executive Officer

View differences made from one to another to evaluate Redhill Biopharma Ltd.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Redhill Biopharma Ltd..


Assess how Redhill Biopharma Ltd.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Redhill Biopharma Ltd.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Material Contracts, Statements, Certifications & more

Redhill Biopharma Ltd. provided additional information to their SEC Filing as exhibits

Ticker: RDHL
CIK: 1553846
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001178913-22-001087
Submitted to the SEC: Tue Mar 15 2022 9:02:37 AM EST
Accepted by the SEC: Tue Mar 15 2022
Period: Tuesday, March 15, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: